SRT2183 | CAS#1001908-89-9 | Sirt1 activator

MedKoo Cat#: 406480 | Name: SRT2183

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SRT2183 is a Sirt1 activator, currently being developed by Sirtris Pharmaceuticals. SRT2183 has similar activity in the body to another SIRT1 activator SRT1720 , but is closer in potency to resveratrol. In animal studies it was found to improve insulin sensitivity and lower plasma glucose levels in fat, muscle and liver tissue, and increased mitochondrial and metabolic function. However, the claim that SRT2183 is a SIRT1 activator has been questioned and further defended.

Chemical Structure

SRT2183

CAS#1001908-89-9

Theoretical Analysis

MedKoo Cat#: 406480

Name: SRT2183

CAS#: 1001908-89-9

Chemical Formula: C27H24N4O2S

Exact Mass: 468.1620

Molecular Weight: 468.57

Elemental Analysis: C, 69.21; H, 5.16; N, 11.96; O, 6.83; S, 6.84

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

SRT2183; SRT 2183; SRT-2183.

IUPAC/Chemical Name

(R)-N-(2-(3-((3-hydroxypyrrolidin-1-yl)methyl)imidazo[2,1-b]thiazol-6-yl)phenyl)-2-naphthamide

InChi Key

MUFSINOSQBMSLE-JOCHJYFZSA-N

InChi Code

InChI=1S/C27H24N4O2S/c32-22-11-12-30(15-22)14-21-17-34-27-29-25(16-31(21)27)23-7-3-4-8-24(23)28-26(33)20-10-9-18-5-1-2-6-19(18)13-20/h1-10,13,16-17,22,32H,11-12,14-15H2,(H,28,33)/t22-/m1/s1

SMILES Code

O=C(NC1=CC=CC=C1C2=CN3C(SC=C3CN4C[C@H](O)CC4)=N2)C5=CC=C6C=CC=CC6=C5

Appearance

white solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 468.57 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Scuto A, Kirschbaum M, Buettner R, Kujawski M, Cermak JM, Atadja P, Jove R. SIRT1 activation enhances HDAC inhibition-mediated upregulation of GADD45G by repressing the binding of NF-κB/STAT3 complex to its promoter in malignant lymphoid cells. Cell Death Dis. 2013 May 16;4:e635. doi: 10.1038/cddis.2013.159. PubMed PMID: 23681230; PubMed Central PMCID: PMC3674366. 2: Nelson LE, Valentine RJ, Cacicedo JM, Gauthier MS, Ido Y, Ruderman NB. A novel inverse relationship between metformin-triggered AMPK-SIRT1 signaling and p53 protein abundance in high glucose-exposed HepG2 cells. Am J Physiol Cell Physiol. 2012 Jul 1;303(1):C4-C13. doi: 10.1152/ajpcell.00296.2011. Epub 2012 Feb 29. PubMed PMID: 22378745; PubMed Central PMCID: PMC3404529. 3: Huber JL, McBurney MW, Distefano PS, McDonagh T. SIRT1-independent mechanisms of the putative sirtuin enzyme activators SRT1720 and SRT2183. Future Med Chem. 2010 Dec;2(12):1751-9. doi: 10.4155/fmc.10.257. PubMed PMID: 21428798. 4: He W, Wang Y, Zhang MZ, You L, Davis LS, Fan H, Yang HC, Fogo AB, Zent R, Harris RC, Breyer MD, Hao CM. Sirt1 activation protects the mouse renal medulla from oxidative injury. J Clin Invest. 2010 Apr;120(4):1056-68. doi: 10.1172/JCI41563. Epub 2010 Mar 24. PubMed PMID: 20335659; PubMed Central PMCID: PMC2846063. 5: Pacholec M, Bleasdale JE, Chrunyk B, Cunningham D, Flynn D, Garofalo RS, Griffith D, Griffor M, Loulakis P, Pabst B, Qiu X, Stockman B, Thanabal V, Varghese A, Ward J, Withka J, Ahn K. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J Biol Chem. 2010 Mar 12;285(11):8340-51. doi: 10.1074/jbc.M109.088682. Epub 2010 Jan 8. PubMed PMID: 20061378; PubMed Central PMCID: PMC2832984. 6: Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, Gagne DJ, Jin L, Boss O, Perni RB, Vu CB, Bemis JE, Xie R, Disch JS, Ng PY, Nunes JJ, Lynch AV, Yang H, Galonek H, Israelian K, Choy W, Iffland A, Lavu S, Medvedik O, Sinclair DA, Olefsky JM, Jirousek MR, Elliott PJ, Westphal CH. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature. 2007 Nov 29;450(7170):712-6. PubMed PMID: 18046409; PubMed Central PMCID: PMC2753457.